**MONOGENIC DIABETES**

**Tiinamaija Tuomi, MD, PhD,** Folkhälsan Research Center, Helsinki, FinlandResearch Programs Unit, Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland Abdominal Center, Endocrinology, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandFinnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland**Päivi J. Miettinen, MD, PhD,** Children’s Hospital, University of Helsinki and Helsinki University Hospital, Finland,Children’s Hospital, University of Helsinki and Helsinki University Hospital, Finland  
BSCC & Research Programs Unit, Molecular Neurology, University of Helsinki, Finland**Liisa Hakaste, MD, PhD,** Folkhälsan Research Center, Helsinki, FinlandResearch Programs Unit, Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland Abdominal Center, Endocrinology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland **Leif Groop, MD, PhD,**Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, FinlandLund University Diabetes Centre, Malmo, Sweden

**Updated: Feb 6th 2015**

**ABSTRACT**

At least 10% of diabetes cannot be attributed to the most common forms, Type 1 or Type 2 diabetes. Maturity-Onset Diabetes of Young (MODY) can be diagnosed in (non-obese) patients with diabetes at a young age, often less than 25 years, who have a strong autosomal dominant family history of diabetes. Patients are generally heterozygous for the different mutations as the homozygous conditions result often in permanent neonatal diabetes. The genetic defects behind MODY and neonatal diabetes cause impaired insulin synthesis or secretion or a reduced beta cell mass due to mutations in genes that are important for beta cell biology. Currently there are more than 10 genes associated with these disorders, and more genes are likely to be identified.

**GENETIC DEFECTS OF BETA-CELL FUNCTION**

|  |
| --- |
| **Table 1. Genetic Defects of Beta-Cell Development and Function** |
| HNF-1 alpha -diabetes  Glucokinase diabetes  HNF-4 alpha diabetes  Pdx1 diabetes  HNF-1 beta diabetes  NeuroD1 diabetes  KLF11 diabetes  CEL diabetes  Pax4 diabetes  Insulin diabetes  BLK diabetes  ABCC8 gene/ Sur1 diabetes  KJCN11 gene/ Kir6.2 diabetes  Neonatal diabetes (permanent or transient) |

**AUTOSOMAL DOMINANT DISEASE**

Historically, before the current epidemic of teenage T2DM (1,2), many patients diagnosed with T2DM or T1DM were found to have a form of diabetes with a strong family history of diabetes, which was labeled Maturity-Onset Diabetes of Young (MODY) in 1965. Although some of them phenotypically resemble T2DM, these individuals are not typically obese and have onset of disease at a young age, generally less than 25 years. Inheritance of the diabetes in these individuals is autosomal dominant with up to 85-95% penetrance. Patients are generally heterozygous for the different mutations as the homozygous conditions result often in permanent neonatal diabetes. The genetic defects cause impaired insulin synthesis or secretion or a reduced beta cell mass due to mutations in genes that are important for beta cell biology (3). Currently there are at least 13 genes associated with this disorder, although more genes are likely to be identified in the future (4). Instead of MODY the specific genetic defects are included in the names of the monogenic forms.

**Hepatocyte Nuclear Factor (HNF-4A) Diabetes (Formerly MODY 1)**

This is the first MODY to be described. HNF-4α belongs to the nuclear receptor superfamily of transcription factors and is found in the liver, intestine, kidney, and pancreatic islets. Although it binds DNA as a zinc finger motif there is no defined ligand. It is involved in the regulation of genes required for glucose transport and metabolism (5,6). Patients with HNF4-α diabetes are seldom diagnosed before adolescence. A diagnostic clue can be low triglycerides (0.5- 0.8 mmol/l) (7,8) and the patient may also have been LGA as a newborn and have had a neonatal hyperinsulinemic hypoglycemia (9). Fasting plasma glucose can be quite normal for several years although postprandial glucose and HbA1c is high. Eventually HNF-4A patients require either oral hypoglycemic agents or insulin treatment. Exocrine pancreatic insufficiency can be present.

**Glucokinase (GCK) Diabetes (Formerly MODY 2)**

Heterozygous inactivating mutations in glucokinase cause defects in function (10,11,12,13). This glycolytic enzyme has a low affinity for glucose and controls the rate-limiting step of glucose metabolism. It is referred to as the glucose sensor of the β-cell as it controls glucose-mediated insulin release. More than 60 different mutations have been described and all ethnic groups can be affected. The clinical disease manifests as mild fasting hyperglycemia with onset during infancy but high postprandial glucose levels are very rare even later in life. Severe hyperglycemia and vascular complications are rare in GCK diabetes (14). Treatment consists basically of dietary (avoiding large quantities of carbohydrate) and lifestyle interventions. Homozygotic inactivating GCK mutations lead to permanent neonatal diabetes (15).

**HNF-1A Diabetes (Formerly MODY 3)**

Mutations in HNF-1A are a common cause of MODY (6,16). HNF-1A is part of the homeodomain-containing superfamily of transcription factors. It has a DNA binding motif, and is involved in the genetic control of development and its expression is partly controlled by HNF-4-alpha (17,18). HNF-1A is expressed in the liver, kidney, intestine, and pancreatic islets (19). Over 90 different mutations have been identified and these occur in all ethnic groups, though it is more common in those of European origin (20). Similar to (HNF-4A) diabetes, fasting plasma glucose can be quite normal for several years although postprandial glucose and HbA1c is high. Glucosuria is often part of the clinical presentation, and diabetic complications are often present. Besides diet intervention, most patients will do well on sulfonylurea treatment.

**Pdx1 (a.k.a. Insulin Promotor Factor IPF-1) Diabetes (Formerly MODY4)**

Only a few families have been identified with this disorder (21). Pdx1 is a homeodomain-containing transcription factor that is expressed in the endoderm already before the pancreatic anlage is identifiable (22). It regulates the development of beta and delta cells (23) and therefore it is not surprising that homozygotic or two different heterozygotic mutations lead to pancreatic agenesis and neonatal diabetes (24,25) while single heterozygotic mutations associate with beta cell dysfunction and type 2 like diabetes (21,26). The average age at diagnosis is 35 years (variation between 16-76 years), yet not all mutation carriers develop diabetes (27).

**HNF-1-Beta Diabetes (Formerly MODY 5)**

This form of diabetes is caused by heterozygotic mutations in *TCF2* gene encoding HNF-1beta, and is characterized by progressive non-diabetic renal dysfunction of variable severity, pancreatic atrophy and genital abnormalities (28,29). It is also called RCAD i.e. renal cysts and diabetes. HNF-1beta is expressed in the liver, kidney, intestine, stomach, lung, ovary and pancreatic islets (30). Recently, complete deletion of HNF-1b and 17q12 microdeletion syndrome have been considered to be the same genetic disorder (31). Half of the carriers develop diabetes and are usually treated with insulin because of pancreatic atrophy.

**Neuro D1 Diabetes (Formerly MODY6)**

NeuroD1 (Beta2) is a basic-loop-helic transcription factor involved in pancreatic and neuronal development. Interestingly, heterozygotic Neuro D1 mutation leads to diabetes at the age of 20-40 years (32,33) while mutations in both alleles result in neonatal diabetes with neurological abnormalities and learning disabilities (34).

**KLF11 Diabetes (Formerly MODY7)**

Krüppel-like factor (KLF)-11 is a zinc-finger transcription factor and in regulates transcription of Pdx1 and insulin genes (35,36). Mutations of KLF-11 result in a type 2-like diabetes.

**CEL Diabetes (Formerly MODY8)**

Carboxy ester lipase (CEL) is expressed in pancreatic acinar cells and its mutations result in pancreatic atrophy, fibrosis and lipomatosis together with exocrine insufficiency and later also endocrine dysfunction and diabetes (37). Patients usually need insulin treatment and pancreatic enzyme replacement therapy.

**Pax4 Diabetes (Formerly MODY9)**

Pax4 is a crucial transcription factor of pancreatic beta and delta cells (38), and its deletion in mouse models leads to lack of beta and delta cells and death from diabetes soon after birth. In humans, Pax4 gene mutations have been detected in only a few patients with a phenotype similar to type 2 diabetes and it has also been associated with ketosis-prone diabetes (39,40).

**Insulin Diabetes (Formerly MODY10)**

Over 25 mutations have been reported in the preproinsulin gene leading to diabetes at various ages (41-43). The treatment is generally insulin although some patients manage with metformin or diet intervention. Interestingly, only a few patients develop late-complications.

**BLK Diabetes (Formerly MODY11)**

Mutations in the B-lymphocyte kinase (BLK) have been reported to cause a dominantly inherited diabetes in three families (44). BLK is a nonreceptor tyrosine-kinase of the *src* family of proto-oncogenes and it regulates insulin synthesis and secretion in beta cells through transcription factors Pdx1 and Nkx6.1.

**ABCC8 Gene/ SUR1 Diabetes (Formerly MODY12)**

SUR1 is encoded by the *ABCC8* gene and it is a part of the K-ATP-channel (45). Its activating homo- and heterozygous mutations cause neonatal diabetes, but heterozygous mutations can also cause MODY in patients whose clinical features are similar to those with HNF1A/4A diabetes (46). The correct molecular diagnosis is important as the patients can be treated with sulfonylureas.

**KJCN11 gene/ Kir6.2 Diabetes (Formerly MODY13)**

Kir6.2 is encoded by *KJCN11* gene and it is a part of the K-ATP-channel (45). Similar to SUR1, its activating homozygous mutations cause neonatal diabetes, but heterozygous mutation has been associated with a large spectrum of diabetes phenotypes in a French family and was not totally penetrant (47). The age at diagnosis varied from childhood to adulthood and the treatment from diet to OHA or insulin.

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 2. MODY Characteristics** | | | |
| **MODY type** | **Frequency (% from MODYs)** | **Age at diagnosis (y)** | **Hyperglycemia** |
| **GKC** | 15-20 | newborn or older | Mild |
| **HNF-4A** | 5 | From puberty | Progressive |
| **HNF-1A** | almost 60 | From puberty | Progressive |
| **HNF-1B** | 2 | > 20 | Progressive |
| **Pdx1** | < 1 | > 35 | Progressive |
| **Ins** | 2 | Infant to adult | Varies |
| **CEL** | < 1 | > 30 | N.A |
| **NeuroD** | < 1 | 20-30 | Progressive |
| **KLF11** | < 1 | 20-30 | Variable |
| **Pax4** | < 1 | > 20 | Progressive |
| **Kir6.2** | < 1 | From early puberty to adulthood | Variable |
| **SUR1** | < 1 | From early puberty to adulthood | Variable |


|  |  |  |  |
| --- | --- | --- | --- |
| **Table 2. MODY Characteristics** | | | |
| **MODY Types** | **Complications** | **Other Features** | **Treatment** |
| **GKC** | Very rare | Mild hyperglycemia already from newborn, homozygote: PNDM | Diet |
| **HNF-4A** | as T1D | Neonatal hyperinsulinemia, LGA, low triglycerides | OHA or insulin |
| **HNF-1A** | as T1D | reduced renal glucose threshold | OHA or insulin |
| **HNF-1B** | as T1D | Renal anomalies, renal insufficiency, pancreatic hypoplasia, genital anomalies | OHA or insulin |
| **Pdx1** | NA | Homozygote: pancreatic agenesis | Diet or OHA or insulin |
| **Ins** | Mild but can be as T1D | Can also present as PNDM | Diet or OHA or insulin |
| **CEL** | NA | Exocrine insufficiency, lipomatosis | OHA or insulin |
| **NeuroD** | NA | Homozygote: PNDM and neurological abnormalities | OHA or insulin |
| **KLF11** | NA | NA. | OHA or insulin |
| **Pax4** | NA | NA. | Diet or OHA or insulin |
| **Kir6.2** | NA | Homozygote: neonatal diabetes | Diet or OHA or insulin |
| **SUR1** | NA | Homozygote: permanent neonatal diabetes; heterozygote: transient neonatal diabetes | OHA (sulfonylurea) |

**Permanent and Transient Neonatal Diabetes**

Neonatal diabetes (NDM) is a diabetes that manifests during the first six months of life and it can be divided into permanent (PNDM) and transient (TNDM) forms. In this age group the most likely etiology is monogenic instead of autoimmune, and the diabetes can present either as isolated or a part of a syndrome (48-51). The incidence of NDM is estimated to be 1: 260000 (52). Recently, Flanagan et al. reported from a cohort of 147 of PNDM patients from consanguineous pedigrees that 75% had mutations in non-transcription factor genes (ABCC8 11%*, EIF2AK3 40%, GCK 17%, INS 16%, KCNJ11 8%, SLC19A2 5%, SLC2A2 2%*), and 7.5% in developmentally important pancreatic transcription factors (PDX1, *PTF1A, GLIS3, RFX6, NEUROD1, NKX2.2, MNX1)* (53). Furthermore, mutations in other pancreatic transcription factor genes (*PAX6, NEUROG3, GATA4, GATA6, STAT3, FOXP3)* have been identified in patients with neonatal diabetes (54-60).

It is important to get the exact molecular diagnosis behind NDM since the patients can be treated life-long with sulfonylureas instead of insulin in case of SUR1 or Kir6.2 mutations (38).

Most of TNDM is caused by abnormalities of an imprinted locus on chromosome 6q24 that results in the overexpression of the paternally expressed gene. Approximately 5% of these cases are due to recessive ZFP57 mutations, causing hypomethylation at the TNDM locus and other maternally imprinted loci (e.g. PEG3/ZIM2 and GRB10) and 25% are caused by mutations in either *KJCN11* or *ABCC8* genes (61).



**Figure 1. Mutation in genes governing beta cell development and function reduce beta cell mass and impair insulin secretion resulting in diabetes (modified from Folias & Hebrok, Nat Rev Endocrinol 2014) (62).**

**REFERENCES**

1. Rocchini AP. Childhood obesity and a diabetes epidemic. N Engl J Med. 2002;346(11):854-855.

2. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346(11):802-810.

3. Fajans SS, Bell GI. MODY: History, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34(8):1878-1884.

4. McDonald TJ, Ellard S. Maturity onset diabetes of the young: Identification and diagnosis. Ann Clin Biochem. 2013;50(Pt 5):403-415.

5. Bell GI, Xiang KS, Newman MV, et al. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc Natl Acad Sci U S A. 1991;88(4):1484-1488.

6. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature. 1996;384(6608):458-460.

7. Lehto M, Bitzen PO, Isomaa B, et al. Mutation in the HNF-4alpha gene affects insulin secretion and triglyceride metabolism. Diabetes. 1999;48(2):423-425.

8. Shih DQ, Stoffel M. Molecular etiologies of MODY and other early-onset forms of diabetes. Curr Diab Rep. 2002;2(2):125-134.

9. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4):e118.

10. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356(6365):162-164.

11. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356(6371):721-722.

12. Chiu KC, Province MA, Permutt MA. Glucokinase gene is genetic marker for NIDDM in american blacks. Diabetes. 1992;41(7):843-849.

13. Kesavan P, Wang L, Davis E, et al. Structural instability of mutant beta-cell glucokinase: Implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2). Biochem J. 1997;322 ( Pt 1)(Pt 1):57-63.

14. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279-286.

15. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11):1512-1526.

16. Vaxillaire M, Boccio V, Philippi A, et al. A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. Nat Genet. 1995;9(4):418-423.

17. Gragnoli C, Lindner T, Cockburn BN, et al. Maturity-onset diabetes of the young due to a mutation in the hepatocyte nuclear factor-4 alpha binding site in the promoter of the hepatocyte nuclear factor-1 alpha gene. Diabetes. 1997;46(10):1648-1651.

18. Gupta RK, Vatamaniuk MZ, Lee CS, et al. The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest. 2005;115(4):1006-1015.

19. Blumenfeld M, Maury M, Chouard T, Yaniv M, Condamine H. Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development. 1991;113(2):589-599.

20. Hansen T, Eiberg H, Rouard M, et al. Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: Evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes. 1997;46(4):726-730.

21. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet. 1997;17(2):138-139.

22. Ohlsson H, Edlund T. Sequence-specific interactions of nuclear factors with the insulin gene enhancer. Cell. 1986;45(1):35-44.

23. Babu DA, Deering TG, Mirmira RG. A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis. Mol Genet Metab. 2007;92(1-2):43-55.

24. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 1997;15(1):106-110.

25. Schwitzgebel VM, Mamin A, Brun T, et al. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab. 2003;88(9):4398-4406.

26. Nicolino M, Claiborn KC, Senee V, Boland A, Stoffers DA, Julier C. A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. Diabetes. 2010;59(3):733-740.

27. Fajans SS, Bell GI, Paz VP, et al. Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60. Transl Res. 2010;156(1):7-14.

28. Sovik O, Sagen J, Njolstad PR, Nyland H, Myhr KM. Contributions to the MODY5 phenotype. J Inherit Metab Dis. 2002;25(7):597-598.

29. Weng JP, Lehto M, Forsblom C, Huang X, Li H, Groop LC. Hepatocyte nuclear factor-1 beta (MODY5) gene mutations in scandinavian families with early-onset diabetes or kidney disease or both. Diabetologia. 2000;43(1):131-132.

30. Bellanne-Chantelot C, Clauin S, Chauveau D, et al. Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes. 2005;54(11):3126-3132.

31. Laffargue F, Bourthoumieu S, Llanas B, et al. Towards a new point of view on the phenotype of patients with a 17q12 microdeletion syndrome. Arch Dis Child. 2014.

32. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999;23(3):323-328.

33. Gonsorcikova L, Pruhova S, Cinek O, et al. Autosomal inheritance of diabetes in two families characterized by obesity and a novel H241Q mutation in NEUROD1. Pediatr Diabetes. 2008;9(4 Pt 2):367-372.

34. Rubio-Cabezas O, Minton JA, Kantor I, Williams D, Ellard S, Hattersley AT. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes. 2010;59(9):2326-2331.

35. Fernandez-Zapico ME, van Velkinburgh JC, Gutierrez-Aguilar R, et al. MODY7 gene, KLF11, is a novel p300-dependent regulator of pdx-1 (MODY4) transcription in pancreatic islet beta cells. J Biol Chem. 2009;284(52):36482-36490.

36. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 2005;102(13):4807-4812.

37. Johansson BB, Torsvik J, Bjorkhaug L, et al. Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): A protein misfolding disease. J Biol Chem. 2011;286(40):34593-34605.

38. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature. 1997;386(6623):399-402.

39. Shimajiri Y, Sanke T, Furuta H, et al. A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in japanese. Diabetes. 2001;50(12):2864-2869.

40. Mauvais-Jarvis F, Smith SB, Le May C, et al. PAX4 gene variations predispose to ketosis-prone diabetes. Hum Mol Genet. 2004;13(24):3151-3159.

41. Glaser B. Insulin mutations in diabetes: The clinical spectrum. Diabetes. 2008;57(4):799-800.

42. Molven A, Ringdal M, Nordbo AM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008;57(4):1131-1135.

43. Meur G, Simon A, Harun N, et al. Insulin gene mutations resulting in early-onset diabetes: Marked differences in clinical presentation, metabolic status, and pathogenic effect through endoplasmic reticulum retention. Diabetes. 2010;59(3):653-661.

44. Borowiec M, Liew CW, Thompson R, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106(34):14460-14465.

45. Clement JP,4th, Kunjilwar K, Gonzalez G, et al. Association and stoichiometry of K(ATP) channel subunits. Neuron. 1997;18(5):827-838.

46. Bowman P, Flanagan SE, Edghill EL, et al. Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia. 2012;55(1):123-127.

47. Bonnefond A, Philippe J, Durand E, et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One. 2012;7(6):e37423.

48. von Muhlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med. 1995;333(11):704-708.

49. Njolstad PR, Sovik O, Cuesta-Munoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344(21):1588-1592.

50. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838-1849.

51. Rubio-Cabezas O, Hattersley AT, Njolstad PR, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15 Suppl 20:47-64.

52. Slingerland AS, Shields BM, Flanagan SE, et al. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three european countries of at least 1 in 260,000 live births. Diabetologia. 2009;52(8):1683-1685.

53. Flanagan SE, De Franco E, Lango Allen H, et al. Analysis of transcription factors key for mouse pancreatic development establishes NKX2-2 and MNX1 mutations as causes of neonatal diabetes in man. Cell Metab. 2014;19(1):146-154.

54. Solomon BD, Pineda-Alvarez DE, Balog JZ, et al. Compound heterozygosity for mutations in PAX6 in a patient with complex brain anomaly, neonatal diabetes mellitus, and microophthalmia. Am J Med Genet A. 2009;149A(11):2543-2546.

55. Rubio-Cabezas O, Minton JA, Caswell R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care. 2009;32(1):111-116.

56. Lango Allen H, Flanagan SE, Shaw-Smith C, et al. GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet. 2011;44(1):20-22.

57. Spiegel R, Dobbie A, Hartman C, de Vries L, Ellard S, Shalev SA. Clinical characterization of a newly described neonatal diabetes syndrome caused by RFX6 mutations. Am J Med Genet A. 2011;155A(11):2821-2825.

58. Shaw-Smith C, De Franco E, Lango Allen H, et al. GATA4 mutations are a cause of neonatal and childhood-onset diabetes. Diabetes. 2014;63(8):2888-2894.

59. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014;46(8):812-814.

60. Rubio-Cabezas O, Jensen JN, Hodgson MI, et al. Permanent neonatal diabetes and enteric anendocrinosis associated with biallelic mutations in NEUROG3. Diabetes. 2011;60(4):1349-1353.

61. Boonen SE, Mackay DJ, Hahnemann JM, et al. Transient neonatal diabetes, ZFP57, and hypomethylation of multiple imprinted loci: A detailed follow-up. Diabetes Care. 2013;36(3):505-512.

62. Folias AE, Hebrok M. Diabetes. solving human beta-cell development--what does the mouse say? Nat Rev Endocrinol. 2014;10(5):253-255.